Vemurafenib is under clinical development by F. Hoffmann-La Roche and currently in the Phase I and Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Vemurafenib’s likelihood of approval (LoA) and phase transition for Bile Duct Cancer (Cholangiocarcinoma) took place on 29 Jun 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway.

In addition, the same event on 29 Jun 2022 increased Vemurafenib’s LoA and PTSR for Gastrointestinal Stromal Tumor (GIST), increased LoA and PTSR for Hairy Cell Leukemia, increased LoA and PTSR for Lymphoma, increased LoA and PTSR for Neuroblastoma, increased PTSR for Ovarian Cancer, increased LoA and PTSR for Refractory Multiple Myeloma, increased PTSR for Relapsed Multiple Myeloma, increased LoA and PTSR for Sarcomas, and increased LoA and PTSR for Thyroid Cancer.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Vemurafenib Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Vemurafenib overview

Vemurafenib (Zelboraf, RG7204, PLX4032, RO5185426) is a phenylpyridine derivative, acts as an antineoplastic agent. It is formulated as film-coated tablets for oral route of administration. Zelboraf tablets are indicated in monotherapy for the treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma.

It is under development for the treatment of solid tumor including lung adenocarcinoma, pancreatic cancer, papillary thyroid cancer, non-small cell lung cancer, neuroblastoma, lymphomas, ovarian cancer, cholangiocarcinoma, prostate cancer, bladder cancer, sarcoma, stages I-III non-small cell lung cancer with ALK, ROS1, NTRK, or BRAF v600E molecular alterations, thyroid cancer, gastrointestinal stromal tumor (GIST) and chronic lymphocytic leukemia (CLL), refractory and relapsed multiple myeloma, refractory and relapsed hairy cell leukemia. It was also under development for metastatic melanoma, colorectal cancer and pediatric gliomas.

F. Hoffmann-La Roche overview

F. Hoffmann-La Roche (Roche) is a biotechnology company that develops drugs and diagnostics to treat major diseases. It provides medicines for the treatment of cancer, other auto-immune diseases, central nervous system disorders, ophthalmological disorders, infectious diseases, and respiratory diseases. The company also offers in vitro diagnostics, tissue-based cancer diagnostics, and diabetes management solutions. Roche conducts research to identify novel methods to prevent, diagnose, and treat diseases. The company offers its products and services to hospitals, commercial laboratories, healthcare professionals, researchers, and pharmacists. Together with its subsidiaries and partners, the company has operations in various countries. Roche is headquartered in Basel, Switzerland.

Quick View Vemurafenib LOA Data

Report Segments
  • Innovator (NME)
Drug Name
  • Vemurafenib
Administration Pathway
  • Oral
Therapeutic Areas
  • Hematological Disorders
  • Oncology
Key Developers
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.